...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
【24h】

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

机译：Tofogliflozin对老年糖尿病患者心脏功能的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction (EF). Recent clinical data suggest that several sodium glucose transporter-2 (SGLT2) inhibitors are found to reduce cardiovascular disease (CVD) events in elderly diabetic patients, but the effect of tofogliflozin, one of the SGLT2 inhibitors, on CVD is unknown. We retrospectively investigated the effect of tofogliflozin on cardiac function in elderly patients with T2DM.Methods:Patients received 20 mg of tofogliflozin daily for 1 month. EF, ratio of early filling to atrial filling (E/A), a change in mitral inflow E and mitral e' annular velocities (E/e'), left atrial dimension (LAD) and maximal diameter of inferior vena cava (IVCmax) were measured between baseline and 1 month after the administration of tofogliflozin.Results:Body weight, systolic and diastolic blood pressures significantly decreased, while renin and aldosterone level significantly increased after 1 month of tofogliflozin treatment. Most of the physiological parameters and the level of serum electrolyte did not change significantly. E/A, E/e' and LAD significantly decreased, while no significant changes were observed in EF and IVCmax. The interactions of E/e' between time, gender and age were not significant.Conclusion:The present study suggested that tofogliflozin improved left ventricular diastolic function irrespective of gender and age, while preserving IVC, renal function and electrolyte balance.Copyright 2020, Higashikawa et al.
机译：背景：2型糖尿病（T2DM）的患者在舒张声弛豫和心力衰竭中造成的损伤风险增加，并且具有保存的喷射部分（EF）。最近的临床资料表明，发现几种葡萄糖转运蛋白-2（SGLT2）抑制剂在老年糖尿病患者中减少心血管疾病（CVD）事件，但Tofoglozin的作用是CGD，CVD中的一种。我们回顾性地研究了Tofogliflozin对老年T2DM患者心脏功能的影响。方法：患者每天接受20毫克Tofoglozin 1个月。 EF，早期填充到心房填充（E / A）的比率，二尖瓣流入E和二尖瓣E'环形速度（E / E'）的变化，左心房尺寸（LAD）和下腔静脉的最大直径（IVcmax）在基线之间测量和培育Tofogliflozin的1个月。结果：体重，收缩性和舒张血压显着降低，而肾素和醛固酮水平在1个月的Tofogliflozin治疗后显着增加。大多数生理参数和血清电解质的水平没有显着变化。 E / A，E / E'和LAD显着降低，而EF和IVCmax在EF和IVCmax中没有观察到显着变化。 E / E之间的相互作用，性别和年龄之间的相互作用并不重要。结论：本研究表明，Tofogliflozin改善左心室舒张功能，无论性别和年龄如何，在保留IVC，肾功能和电解质平衡时。2020，Higashikawa等等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号